Reassessing the comparison of foreign drug pricing is 'idle'
By Lee, Tak-Sun | translator Kang, Shin-Kook
24.07.08 05:59:42
가나다라
0
Industry argues that comparing public reimbursement prices of Germany and Canada will distort the results
The government and pharmaceutical industry confirmed their differences in opinions at the 10th meeting
It’s uncertain whether there will be a meeting in the future…the two parties may continue to communicate privately
The 10th public-private meeting has been held to reassess the comparative methods of foreign drug pricing. However, they exchanged different opinions without reaching a concrete decision.
Pharmaceutical industry has particularly opposed to the use of drug pricing references from Germany and Canada. It remains to be seen how the two parties will continue the discussion regarding this matter.
According to industry sources, the 10th meeting to reassess the comparative methods of referencing foreign drug pricing was held on the morning of July 5th.
The government initially planned to convene the meeting in June, planning to complete gathering opinions, but due to sched
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)